Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
Posts falsely claim Malaysian minister to relocate public hospital for temple- Wegovy maker Novo sharpens consumer focus with board role for Mars CEO
- Vote in favor of your Number one method for commending a birthday
- ‘Slender Man’ attacker back in custody. What we know about Morgan Geyser's disappearance and what happens next.
- Rick Steves' Newest Guidebook Is A Fresh Perspective On Italy Spilling The Country's Secrets
- U.S. to drop childhood vaccine recommendations as it looks to Denmark, Washington Post reports
- Father and son spending Christmas together after health scares
- Manual for extravagance SUVs for seniors
- 'War is not over': Detailed diagrams of prisons found in cells of Oct. 7 terrorists
